Publications by authors named "Angela de Haas"

Claim this Profile
L
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Angela de Haas

Aliment Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.
Séverine Vermeire, Brian G Feagan, Laurent Peyrin-Biroulet, Alessandra Oortwijn, Margaux Faes, Angela de Haas

J Crohns Colitis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe, Séverine Vermeire, Christian Maaser, Angela de Haas

Aliment Pharmacol Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
Iris Dotan, Brian G Feagan, Virginia Taliadouros, Alessandra Oortwijn, Christine Rudolph, Angela de Haas

J Crohns Colitis· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis